Search

Your search keyword '"Kawashiri, S-Y"' showing total 89 results
Start Over Author "Kawashiri, S-Y"
89 results on '"Kawashiri, S-Y"'

1. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study

Author

Michitsuji, T, primary, Fukui, S, additional, Morimoto, S, additional, Endo, Y, additional, Nishino, A, additional, Nishihata, S, additional, Tsuji, Y, additional, Shimizu, T, additional, Umeda, M, additional, Sumiyoshi, R, additional, Koga, T, additional, Iwamoto, N, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Ohtsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nawata, M, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, Kawakami, A, additional, and Kawashiri, S-Y, additional

Published
2023
Full Text
View/download PDF

3. AB0157 EFFICACY AND SAFETY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE: COMPARATIVE STUDY WITH FILGOTINIB AND TOCILIZUMAB EXAMINED BY CLINICAL INDEX AS WELL AS MUSCULOSKELETAL ULTRASOUND ASSESSMENT (TRANSFORM STUDY): STUDY PROTOCOL

Author

Shimizu, T., primary, Kawashiri, S. Y., additional, Morimoto, S., additional, Kawazoe, Y., additional, Kuroda, S., additional, Kawasaki, R., additional, Ito, Y., additional, Sato, S., additional, Yamamoto, H., additional, and Kawakami, A., additional

Published
2022
Full Text
View/download PDF

5. Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan

Author

Endo, Y, primary, Kawashiri, S-Y, additional, Nishino, A, additional, Michitsuji, T, additional, Tomokawa, T, additional, Nishihata, S, additional, Okamoto, M, additional, Tsuji, Y, additional, Tsuji, S, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Koga, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Otsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nawata, M, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2021
Full Text
View/download PDF

7. POS0718 CLINICAL CHARACTERISTICS ASSOCIATED WITH GLANDULAR INVOLVEMENT EVALUATED BY SALIVARY GLAND ULTRASONOGRAPHY IN SJÖGREN’S SYNDROME

Author

Shimizu, T., primary, Nakamura, H., additional, Takagi, Y., additional, Nishihata, S. Y., additional, Sumiyoshi, R., additional, Igawa, T., additional, Koga, T., additional, Kawashiri, S. Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Origuchi, T., additional, and Kawakami, A., additional

Published
2021
Full Text
View/download PDF

10. Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan.

Author

Endo, Y, Kawashiri, S-Y, Nishino, A, Michitsuji, T, Tomokawa, T, Nishihata, S, Okamoto, M, Tsuji, Y, Tsuji, S, Shimizu, T, Sumiyoshi, R, Igawa, T, Koga, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Ueki, Y, and Yoshitama, T

Subjects
*LONGITUDINAL method, *COHORT analysis, *JAPANESE people, *RHEUMATOID arthritis, *ULTRASONIC imaging, *TREATMENT effectiveness
Abstract

This study investigated the effectiveness of treatment with Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA) assessed by ultrasonography (US) activity, and the influence of patient characteristics and previous treatments. This prospective study assessed 60 treatment initiations among 53 Japanese patients diagnosed with RA who underwent treatment with JAK inhibitors during June 2013 to February 2020. Of the 53 patients, seven patients were enrolled in duplicate because they were treated with two different JAK inhibitors at different periods. For each case, the improvement rate on the power Doppler (PD) score was assessed at 6 month follow-up. Median improvement rate of PD score was used to classify cases as either US responders or non-responders, and patient characteristics were compared between the two groups. All indicators of clinical disease activity and US activity showed a significant improvement at 3 months compared with baseline. Although the JAK inhibitor-cycler group and the interleukin-6 (IL-6) inhibitor inadequate response (IR) group tended to show a later improvement for US activity, all indicators of clinical disease activity and US activity showed a significant improvement at 6 months compared with baseline for both groups. Multivariate analysis showed that concomitant methotrexate use and an IR to the previous biologic or targeted-synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) treatment were independently and significantly associated with US responders. Use of a JAK inhibitor in combination with methotrexate and an absence of IR to any previous b/tsDMARDs demonstrated superior effectiveness for patients with RA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. Discrepancy between clinical and ultrasound remissions in rheumatoid arthritis: a multicentre ultrasound cohort study in Japan

Author

Endo, Y, primary, Kawashiri, S-Y, additional, Nishino, A, additional, Okamoto, M, additional, Tsuji, S, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Koga, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Otsubo, H, additional, Takaoka, H, additional, Hamada, H, additional, Tsuru, T, additional, Nagano, S, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2021
Full Text
View/download PDF

12. Fluorescence optical imaging in patients with active rheumatoid arthritis: a comparison with ultrasound and an association with biomarkers

Author

Kawashiri, S-y, primary, Nishino, A, additional, Shimizu, T, additional, Takatani, A, additional, Umeda, M, additional, Koga, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Maeda, T, additional, and Kawakami, A, additional

Published
2020
Full Text
View/download PDF

14. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study

Author

Endo, Y, primary, Koga, T, additional, Kawashiri, S-y, additional, Morimoto, S, additional, Nishino, A, additional, Okamoto, M, additional, Tsuji, S, additional, Takatani, A, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Hamada, H, additional, Tsuru, T, additional, Nagano, S, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2020
Full Text
View/download PDF

15. IL‐15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis

Author

Shimizu, T., primary, Koga, T., additional, Furukawa, K., additional, Horai, Y., additional, Fujikawa, K., additional, Okada, A., additional, Okamoto, M., additional, Endo, Y., additional, Tsuji, S., additional, Takatani, A., additional, Umeda, M., additional, Fukui, S., additional, Sumiyoshi, R., additional, Kawashiri, S.‐y., additional, Iwamoto, N., additional, Igawa, T., additional, Ichinose, K., additional, Tamai, M., additional, Sakamoto, N., additional, Nakamura, H., additional, Origuchi, T., additional, Mukae, H., additional, Kuwana, M., additional, and Kawakami, A., additional

Published
2020
Full Text
View/download PDF

16. AB1232 ORAL DYSBIOSIS REFLECTS THE IMMUNOLOGICAL ALTERATION OF RA REGARDING TO ACPA AND HLA DRB1*SE: NAGASAKI ISLAND STUDY

Author

Tsuji, Y., primary, Tamai, M., additional, Morimoto, S., additional, Sasaki, D., additional, Nagayoshi, M., additional, Nonaka, F., additional, Kawashiri, S. Y., additional, Yanagihara, K., additional, Saito, T., additional, Aoyagi, K., additional, Maeda, T., additional, Matsuda, F., additional, and Kawakami, A., additional

Published
2020
Full Text
View/download PDF

17. FRI0098 ASSOCIATION BETWEEN THE SEROLOGIC STATUS OF ISOTYPE-SPECIFIC AUTOANTIBODIES AND THERAPEUTIC EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT: A PROSPECTIVE ULTRASOUND COHORT STUDY IN JAPAN

Author

Kawashiri, S. Y., primary, Endo, Y., additional, Nishino, A., additional, Shimizu, T., additional, Ueki, Y., additional, Eiraku, N., additional, Okada, A., additional, Matsuoka, N., additional, Yoshitama, T., additional, Nakamura, H., additional, Tamai, M., additional, Origuchi, T., additional, Toes, R., additional, Huizinga, T., additional, and Kawakami, A., additional

Published
2020
Full Text
View/download PDF

18. Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan

Author

Sumiyoshi, R., Hidaka, T., Koga, T., Okada, A., Fukuda, T., Ishii, T., Ueki, Y., Kodera, T., Nakashima, M., Takahashi, Y., Honda, S., Horai, Y., Watanabe, R., Okuno, H., Aramaki, T., Izumiyama, T., Takai, O., Miyashita, T., Kawashiri, S. -Y, Iwamoto, N., Kunihiro Ichinose, Tamai, M., Nakamura, H., Origuchi, T., Eguchi, K., and Kawakami, A.

Subjects
Arthritis, Rheumatoid, Disability Evaluation, Japan, Antirheumatic Agents, Surveys and Questionnaires, Disease Progression, Humans, Severity of Illness Index
Abstract

To determine prognostic factors for the Health Assessment Questionnaire-Disability Index (HAQ-DI) progression in patients with rheumatoid arthritis (RA) in clinical practice.We evaluated 388 biological disease-modifying anti-rheumatic drug (bDMARD)-naïve Japanese patients with RA with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for one year. The Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and the HAQ-DI were assessed every three months. We also evaluated joint destruction using a modified total Sharp score at baseline and at one year. HAQ-DI progression was defined as the yearly progression of HAQ-DI0.1. We performed a multiple logistic regression analysis to explore the factors predicting HAQ-DI progression at one year.HAQ-DI progression was observed in 18% of the patients. The multiple logistic regression analysis revealed the independent variables associated with HAQ-DI progression were: DAS28-ESR5.1 at baseline (odds ratio [OR] 0.31, 95% con dence interval [CI] 0.13-0.74, p=0.0083); HAQ-DI score at baseline0.5 (OR 2.27, 95% CI 1.22-4.26, p=0.0102); and achievement of low disease activity at 12 weeks (OR 0.42, 95% CI 0.21-0.82, p=0.0112).Our data suggest that maintaining clinical improvement according to T2T and initiating the treatment at an early stage are important for functional improvement after one year and that patients with low baseline HAQ scores have a higher risk of HAQ disability progression.

Published
2019

19. Effects of cigarette smoking and human T-cell leukaemia virus type 1 infection on anti-citrullinated peptide antibody production in Japanese community-dwelling adults: the Nagasaki Islands Study.

Author

Kawashiri, S-y, Tsuji, Y, Tamai, M, Nonaka, F, Nobusue, K, Yamanashi, H, Maeda, T, and Kawakami, A

Subjects
*MENTHOL, *ANTIBODY formation, *SMOKING, *ADULTS, *CIGARETTE smoke, *LOGISTIC regression analysis
Abstract

Objectives: We investigated whether the positivity of anti-citrullinated peptide antibody (ACPA) is associated with cigarette-smoking status and human T-cell leukaemia virus type 1 (HTLV-1) infection in a general population in Nagasaki, Japan, which is an ageing and HTLV-1-endemic area. Method: Baseline data from community-dwelling people in the Nagasaki Islands Study (NaIS) were included in this cross-sectional analysis. ACPA and HTLV-1 were measured in 3887 subjects without a history of treatment for rheumatoid arthritis. A logistic regression analysis was performed to assess the relationship between ACPA positivity and candidates of correlation with ACPA, i.e. the cigarette-smoking status quantified by Brinkman's index (BI) and HTLV-1 positivity. Results: Fifty-one subjects (1.3%) showed ACPA positivity, and 650 subjects (16.6%) were HTLV-1 carriers. In an age- and gender-adjusted logistic regression analysis, the BI [odds ratio (OR) 1.09, 95% confidence interval (CI)1.02–1.14, p = 0.0031] and a BI value > 500 (OR 3.92, 95% CI 1.72–9.22, p = 0.0014) were each significantly associated with ACPA positivity. HTLV-1 positivity did not show any association with ACPA positivity. Conclusion: A significant effect of cigarette-smoking status on ACPA production was revealed, whereas HTLV-1 positivity was not associated with ACPA production in this general population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan

Author

Endo, Y, primary, Koga, T, additional, Kawashiri, S-Y, additional, Morimoto, S, additional, Nishino, A, additional, Okamoto, M, additional, Eguchi, M, additional, Tsuji, S, additional, Takatani, A, additional, Shimizu, T, additional, Sumiyoshi, R, additional, Igawa, T, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Yoshitama, T, additional, Eiraku, N, additional, Matsuoka, N, additional, Okada, A, additional, Fujikawa, K, additional, Hamada, H, additional, Tsuru, T, additional, Nagano, S, additional, Arinobu, Y, additional, Hidaka, T, additional, Tada, Y, additional, and Kawakami, A, additional

Published
2019
Full Text
View/download PDF

21. Fluorescence optical imaging in patients with active rheumatoid arthritis: a comparison with ultrasound and an association with biomarkers.

Author

Kawashiri, S-y, Nishino, A, Shimizu, T, Takatani, A, Umeda, M, Koga, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Maeda, T, and Kawakami, A

Subjects
*RHEUMATOID arthritis, *ULTRASONIC imaging, *OPTICAL images, *VASCULAR endothelial growth factors, *IMAGING systems, *FLUORESCENCE
Abstract

Objectives: This study compared indocyanine green (ICG)-enhanced fluorescence optical imaging (FOI) and musculoskeletal ultrasound (MSUS), and explored the significance of the FOI findings based on the association between the FOI and MSUS findings and serum biomarkers in patients with rheumatoid arthritis (RA). The study also explored the association between the FOI findings and patients' joint destruction at the joint-area level.Method: We enrolled 50 consecutive patients with active RA from among the patients hospitalized from May 2014 to March 2016 at Nagasaki University Hospital, Japan. FOI images were acquired with the Xiralite® fluorescence imaging system and compared with the patients' clinical examination results and MSUS findings. On the same day, the patients' clinical disease activity and levels of serum biomarkers (including vascular endothelial growth factor) were obtained.Results: Although the FOI detected synovitis with high sensitivity, the frequency of positive findings and the diagnostic performance with MSUS as the reference standard for FOI differed considerably among the phases of FOI as well as among the affected joint regions. The FOI scores were positively correlated with clinical disease activity, MSUS scores, and serum biomarkers. The severity of FOI-proven synovitis was associated with the presence of MSUS-proven bone erosion.Conclusion: FOI is effective for detecting joint inflammation in RA patients, with high accuracy. The severity of the FOI score was closely associated with the joint destruction at the joint-area level. However, the significance of positive FOI findings differed depending on not only the phase of FOI but also the affected joint regions. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. IL‐15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis.

Author

Shimizu, T., Koga, T., Furukawa, K., Horai, Y., Fujikawa, K., Okada, A., Okamoto, M., Endo, Y., Tsuji, S., Takatani, A., Umeda, M., Fukui, S., Sumiyoshi, R., Kawashiri, S.‐y., Iwamoto, N., Igawa, T., Ichinose, K., Tamai, M., Sakamoto, N., and Nakamura, H.

Subjects
INTERSTITIAL lung diseases, POLYMYOSITIS, DERMATOMYOSITIS, LOGISTIC regression analysis, BIOMARKERS, CYTOKINES
Abstract

Background: Polymyositis/dermatomyositis (PM/DM) is an autoimmune disease that is sometimes complicated with rapidly progressive interstitial lung disease (RPILD). However, serum and lung biomarkers that can predict RPILD development remain unclear. Objectives: To determine potential serum and lung biomarkers that can predict RPILD development in patients with PM/DM‐ILD. Methods: In total, 49 patients with PM/DM‐ILD were enrolled. We measured the serum levels of 41 cytokines/chemokines, ferritin and anti‐MDA5 antibody, compared them between the RPILD (n = 23) and non‐RPILD (n = 26) groups, and ranked them by their importance through random forest analysis. To distinguish the two groups, we determined biomarker combinations by logistic regression analysis. We also measured the bronchoalveolar lavage fluid (BALF) levels of 41 cytokines/chemokines. Using immunohistochemistry, we examined IL‐15 expression in lung tissues. The IL‐15 production was also investigated using A549 and BEAS‐2B cells. Results: The RPILD group had significantly higher IL‐15, IL‐1RA, IL‐6, CXCL10, VCAM‐1, anti‐MDA5 antibody and ferritin serum levels than the non‐RPILD group, but it had a significantly low CCL22 level. Meanwhile, anti‐MDA5 antibody, IL‐15, CXCL8, CCL22, IL‐1RA and ferritin were the best combination to distinguish the two groups. IL‐15 and CCL22 were also predictive marker for RPILD development in anti‐MDA5 antibody‐positive patients. Additionally, the RPILD group had significantly high IL‐15 levels in BALF. The lung tissues expressed IL‐15, which increased after cytokine stimulation in the A549 cells. Conclusion: This study identified a combination of biomarkers predicting PM/DM‐RPILD progression, and IL‐15 is an important cytokine for predicting RPILD development and reflecting ILD severity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.

Author

Endo, Y, Koga, T, Kawashiri, S-y, Morimoto, S, Nishino, A, Okamoto, M, Tsuji, S, Takatani, A, Shimizu, T, Sumiyoshi, R, Igawa, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Ueki, Y, Yoshitama, T, Eiraku, N, and Matsuoka, N

Subjects
RHEUMATOID arthritis, ANTIBODY formation, ABATACEPT, COHORT analysis, JAPANESE people
Abstract

Objective: To determine whether the positivity of baseline anti-Ro/Sjögren's syndrome antigen A (SSA) antibodies influences the response to abatacept, we compared therapeutic responses between anti-Ro/SSA antibody-negative and -positive patients with rheumatoid arthritis (RA) using a multicentre RA ultrasonography prospective cohort. Method: We reviewed Japanese patients with RA who started abatacept as the first biological disease-modifying anti-rheumatic drug between June 2013 and April 2018. We assessed 28-joint Disease Activity Score–erythrocyte sedimentation rate (DAS28-ESR) change between baseline and 6 or 12 months after treatment in RA patients treated with abatacept, and European League Against Rheumatism (EULAR) response at 6 and 12 months. The Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated at baseline and at 6 and 12 months. Results: Overall, 51 patients were enrolled and divided into anti-Ro/SSA antibody-negative and -positive groups of 35 and 16, respectively. Median age at baseline was significantly higher in the anti-Ro/SSA antibody-negative group (p = 0.04). The retention rate and percentage of EULAR good responders at 12 months were significantly higher in the anti-Ro/SSA antibody-negative group (both p = 0.02). Anti-Ro/SSA antibody-negative patients exhibited larger decreases in both DAS28-ESR and DAS28-C-reactive protein at 12 months than anti-Ro/SSA antibody-positive patients (p = 0.02 and 0.04, respectively). GLOESS decreased significantly at 6 months in anti-Ro/SSA antibody-negative patients (p = 0.03). Multivariate analyses showed that anti-Ro/SSA antibody positivity was an independent factor associated with change in the DAS28-ESR at 6 months (p < 0.05). Conclusion: Anti-Ro/SSA antibody positivity predicts a poor response to abatacept and low retention rate. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan.

Author

Endo, Y, Koga, T, Kawashiri, S-Y, Morimoto, S, Nishino, A, Okamoto, M, Eguchi, M, Tsuji, S, Takatani, A, Shimizu, T, Sumiyoshi, R, Igawa, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Ueki, Y, Yoshitama, T, and Eiraku, N

Subjects
RHEUMATOID arthritis, TITERS, RHEUMATOID factor, LONGITUDINAL method, COHORT analysis
Abstract

Objective: Successful rheumatoid arthritis (RA) outcome depends on treatment efficacy in the early stages of the disease and its sustainability. It is thus critical to identify factors predicting treatment persistence with biological agents, such as abatacept. We compared clinical profiles, including early changes in autoantibody titres at 3 months, between patients with RA demonstrating sustained persistence and those discontinuing abatacept treatment.Method: We prospectively enrolled 71 and 78 active RA patients treated with abatacept and tumour necrosis factor inhibitors (TNF-Is), respectively, who had previous disease-modifying anti-rheumatic drug) failure. Clinical characteristics were compared between non-continuation and continuation groups stratified according to abatacept or TNF-I persistence for at least 12 months from treatment initiation.Results: Significantly larger decreases in rheumatoid factor titre and anti-citrullinated protein autoantibody (ACPA) titre were observed in the continuation group of abatacept therapy at 3 months, and early reduction in ACPA titre remained a significant and independent predictor of sustained persistence with abatacept in multivariate analysis. In addition, we obtained the area under the receiver operator characteristics curve of 0.904 from a model including baseline ACPA titre and reduction of ACPA titre at 3 months. Sustained reduction of RA disease activity score at 12 months was significantly and independently associated with reduced ACPA titre at 3 months.Conclusions: Persistence with abatacept and sustained therapeutic response are associated with an early reduction in ACPA titre. Prediction of abatacept continuation and efficacy will facilitate the optimal design of therapy in the early stages of RA. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

25. SAT0086 Evaluation of diagnostic performance of magnetic resonance imaging (MRI) and ultrasound (US) toward early rheumatoid arthritis from nagasaki early arthritis cohort

Author

Takatani, A., primary, Tamai, M., additional, Ohki, N., additional, Nakashima, Y., additional, Endo, Y., additional, Tsuji, S., additional, Shimizu, T., additional, Umeda, M., additional, Fukui, S., additional, Sumiyoshi, R., additional, Nishino, A., additional, Koga, T., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Igawa, T., additional, Ichinose, K., additional, Arima, K., additional, Nakamura, H., additional, Origuchi, T., additional, Sato, S., additional, Uetani, M., additional, and Kawakami, A., additional

Published
2018
Full Text
View/download PDF

26. OP0084 Serum fibroblast growth factor 2 is a useful biomarker to distinguish adult onset still disease from sepsis

Author

Koga, T., primary, Sumiyoshi, R., additional, Sato, S., additional, Migita, K., additional, Shimizu, T., additional, Umeda, M., additional, Nonaka, F., additional, Fukui, S., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Yachie, A., additional, Maeda, T., additional, and Kawakami, A., additional

Published
2018
Full Text
View/download PDF

27. SAT0589 Musculoskeletal manifestations occur predominantly in patients with older onset familial mediterranean fever

Author

Endo, Y., primary, Koga, T., additional, Umeda, M., additional, Ishida, M., additional, Fujita, Y., additional, Tsuji, S., additional, Takatani, A., additional, Shimizu, T., additional, Sumiyoshi, R., additional, Igawa, T., additional, Fukui, S., additional, Nishino, A., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Agematsu, K., additional, Yachie, A., additional, Masumoto, J., additional, Mitiga, K., additional, and Kawakami, A., additional

Published
2018
Full Text
View/download PDF

28. The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus

Author

Ichinose, K, primary, Sato, S, additional, Kitajima, Y, additional, Horai, Y, additional, Fujikawa, K, additional, Umeda, M, additional, Fukui, S, additional, Nishino, A, additional, Koga, T, additional, Kawashiri, S Y, additional, Iwamoto, N, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Yasuhi, I, additional, Masuzaki, H, additional, and Kawakami, A, additional

Published
2018
Full Text
View/download PDF

29. Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients

Author

Koga, T, primary, Kawashiri, S-y, additional, Migita, K, additional, Sato, S, additional, Umeda, M, additional, Fukui, S, additional, Nishino, A, additional, Nonaka, F, additional, Iwamoto, N, additional, Ichinose, K, additional, Tamai, M, additional, Nakamura, H, additional, Origuchi, T, additional, Ueki, Y, additional, Masumoto, J, additional, Agematsu, K, additional, Yachie, A, additional, Eguchi, K, additional, and Kawakami, A, additional

Published
2017
Full Text
View/download PDF

33. SAT0533 Early Diagnosis is Associated with the Less Flair in Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome

Author

Origuchi, T., primary, Arima, K., additional, Umeda, M., additional, Kawashiri, S.-Y., additional, Koga, T., additional, Ichinose, K., additional, Tamai, M., additional, Nakamura, H., additional, Miyashita, T., additional, Fujikawa, K., additional, Mizokami, A., additional, Iwanaga, N., additional, Furuyama, M., additional, Nakashima, M., additional, Aramaki, T., additional, Ueki, Y., additional, Kawabe, Y., additional, Fukuda, T., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2015
Full Text
View/download PDF

34. FRI0048 MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort

Author

Tamai, M., primary, Arima, K., additional, Nakashima, Y., additional, Kita, J., additional, Umeda, M., additional, Fukui, S., additional, Nishino, A., additional, Suzuki, T., additional, Horai, Y., additional, Okada, A., additional, Koga, T., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Yamasaki, S., additional, Nakamura, H., additional, Origuchi, T., additional, Aoyagi, K., additional, Uetani, M., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2015
Full Text
View/download PDF

36. AB0180 The Role of Immune Regulation of CD4+CD52High T Cells in Systemic Lupus Erythematosus

Author

Umeda, M., primary, Koga, T., additional, Ichinose, K., additional, Tsuji, S., additional, Fukui, S., additional, Nishino, A., additional, Nakashima, Y., additional, Suzuki, T., additional, Horai, Y., additional, Hirai, Y., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Aramaki, T., additional, Tamai, M., additional, Nakamura, H., additional, Yamamoto, K., additional, Origuchi, T., additional, Ueki, Y., additional, and Kawakami, A., additional

Published
2015
Full Text
View/download PDF

37. FRI0429 Evaluation of Soluble α-Klotho in Neuropsychiatric Systemic Lupus Erythematosus

Author

Ushigusa, T., primary, Ichinose, K., additional, Tsuji, S., additional, Umeda, M., additional, Fukui, S., additional, Nishino, A., additional, Nakashima, Y., additional, Suzuki, T., additional, Horai, Y., additional, Koga, T., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Hirai, Y., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, and Kawakami, A., additional

Published
2015
Full Text
View/download PDF

38. SAT0261 Abatacept is A Suitable Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Anti-Ss-A Antibodies-Positive Rheumatoid Arthritis

Author

Horai, Y., primary, Takatani, A., additional, Nishino, A., additional, Nakashima, Y., additional, Suzuki, T., additional, Fujikawa, K., additional, Tsukada, T., additional, Tsuboi, M., additional, Matsuoka, N., additional, Migita, K., additional, Aramaki, T., additional, Ueki, Y., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

39. AB1018 Articular Synovitis or Tenosynovitis - Which is More Involved toward Functional Disabilities in Patients with Rheumatoid Arthritis? Investigation of Wrist and Finger Joints by Ultrasound in Early-Stage Rheumatoid Arthritis

Author

Kawashiri, S.-Y., primary, Nishino, A., additional, Suzuki, T., additional, Horai, Y., additional, Nakashima, Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Arima, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

40. OP0225 Mefv and TNFRSF1A Gene Mutations in Patients with Inflammatory Myopathy with Abundant Macrophages

Author

Fujikawa, K., primary, Migita, K., additional, Umeda, M., additional, Nonaka, F., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Nakamura, H., additional, Mizokami, A., additional, Tsukada, T., additional, Origuchi, T., additional, Ueki, Y., additional, Yasunami, M., additional, Kawakami, A., additional, and Eguchi, K., additional

Published
2014
Full Text
View/download PDF

41. SAT0252 Disease Activity at 3 Month Predicts the Clinical Response at 1 Year Treated by TOCILIZUMAB in Patients with Active Rheumatoid Arthritis: Results from Observational Investigation of Daily Clinical Practice

Author

Kawashiri, S.-Y., primary, Suzuki, T., additional, Nakashima, Y., additional, Ueki, Y., additional, Aramaki, T., additional, Fujikawa, K., additional, Nakashima, M., additional, Okada, A., additional, Migita, K., additional, Mizokami, A., additional, Matsuoka, N., additional, Ichinose, K., additional, Nakamura, H., additional, Origuchi, T., additional, Aoyagi, K., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

42. SAT0215 Ultrasound Disease Activity at 3 Months Predicts the Clinical Response at 6 Months of Patients with Rheumatoid Arthritis Treated by Biologic Disease Modifying Anti-Rheumatic Drugs

Author

Kawashiri, S.-Y., primary, Nishino, A., additional, Suzuki, T., additional, Nakashima, Y., additional, Horai, Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Arima, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Uetani, M., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

43. OP0117 Surveillance of the Outcome of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome

Author

Origuchi, T., primary, Arima, K., additional, Kawashiri, S.-Y., additional, Tamai, M., additional, Nakamura, H., additional, Kawakami, A., additional, Tsukada, T., additional, Miyashita, T., additional, Aramaki, T., additional, Furuyama, M., additional, Kawabe, Y., additional, Iwanaga, N., additional, Ueki, Y., additional, Fukuda, T., additional, and Eguchi, K., additional

Published
2014
Full Text
View/download PDF

44. AB0646 Low Reactive Hyperemia Index Assessed by Endopat and High Circulating Level of Placenta Growth Factor, Growth Differentiation Factor-15 and Pentraxin-3 Reflect the Presence of Vasculopathy as Well as Progressive Disease Status in Patients with Systemic Sc

Author

Kawashiri, S.-Y., primary, Nishino, A., additional, Nakashima, Y., additional, Suzuki, T., additional, Horai, Y., additional, Nakashima, M., additional, Mizokami, A., additional, Matsuoka, N., additional, Iwamoto, N., additional, Ichinose, K., additional, Arima, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Aoyagi, K., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

45. Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis

Author

Kawashiri, S.-y., primary, Suzuki, T., additional, Nakashima, Y., additional, Horai, Y., additional, Okada, A., additional, Nishino, A., additional, Iwamoto, N., additional, Ichinose, K., additional, Arima, K., additional, Tamai, M., additional, Nakamura, H., additional, Origuchi, T., additional, Uetani, M., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2014
Full Text
View/download PDF

46. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion

Author

Kawashiri, S.-y., primary, Suzuki, T., additional, Nakashima, Y., additional, Horai, Y., additional, Okada, A., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Arima, K., additional, Nakamura, H., additional, Origuchi, T., additional, Uetani, M., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2013
Full Text
View/download PDF

47. FRI0084 The presence of magnetic resonance imaging-proven osteitis at entry predicts the development of rapid radiographic progression in patients with early rheumatoid arthritis

Author

Tamai, M., primary, Nakashima, Y., additional, Suzuki, T., additional, Okada, A., additional, Kita, J., additional, Horai, Y., additional, Kawashiri, S.-Y., additional, Iwamoto, N., additional, Ichinose, K., additional, Arima, K., additional, Yamasaki, S., additional, Nakamura, H., additional, Origuchi, T., additional, Uetani, M., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2013
Full Text
View/download PDF

48. SAT0524 Automated Breast Volume Scanner (ABVS), a New Automated Ultrasonic Device, is Useful to Examine Joint Injury in Patients with Rheumatoid Arthritis

Author

Kawashiri, S.-Y., primary, Suzuki, T., additional, Nakashima, Y., additional, Horai, Y., additional, Okada, A., additional, Iwamoto, N., additional, Ichinose, K., additional, Tamai, M., additional, Arima, K., additional, Nakamura, H., additional, Origuchi, T., additional, Uetani, M., additional, Aoyagi, K., additional, Eguchi, K., additional, and Kawakami, A., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results